Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and Turkey

Creative Commons License

Semin S., Aras Ş., Guldal D.

HEALTH EXPECTATIONS, vol.10, no.1, pp.4-15, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 10 Issue: 1
  • Publication Date: 2007
  • Doi Number: 10.1111/j.1369-7625.2006.00411.x
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
  • Page Numbers: pp.4-15
  • Keywords: direct-to-consumer advertising, drug information, drug promotion, PRESCRIPTION DRUGS, INDUSTRY, TRENDS
  • Dokuz Eylül University Affiliated: Yes


While several major problems concerning drugs occur in the world, the attempts to direct-to-consumer advertising (DTCA) has gained a considerable impetus lately in both developed and developing countries. DTCA has increasingly become an appealing advertising alternative for the pharmaceutical industry as drug companies have come to wrestle with such problems as the expansion of the drug market; the decline of the medical representatives' work efficiency; drug reimbursement restrictions; and the escalating role of the Internet in the consumer market. Some of the main disadvantages of the DTCA are: increasing drug expenditures, unnecessary drug consumption and adverse effect risks. Even though the influence of pharmaceuticals on health services and the economy hold the same importance in the developed and developing countries, its negative consequences have increased by encompassing developing countries in its grip. Therefore, in this review, using Turkey as an example, the situation of direct-to-consumer advertisements in developing countries is analysed in relation with developed countries.